Blastic Leukemia Complicating Reticulo-Sarcoma and Lympho-Sarcoma

Schlumberger, Jean; Mathé, G; Texier, J L; Amiel, J. L.; Cattan, A; Schwarzenberg, L; Schneider, M.; Berumen, L

doi:10.1007/978-3-662-35334-9_25

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1972

1978

Publication Types

Select...

Article1

Book1

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Daunorubicin therapy in adult acute lymphatic leukemia

Bloomfield

Brunning

Kennedy

1972

Cancer

View full text Add to dashboard Cite

Twelve adults with acute lymphatic leukemia, all but one of whom had relapsed while being treated with the usual antileukemic agents, were treated with daunorubicin and prednisone. Two complete and three partial remissions were obtained. The average duration of remission was 3 months. Daunorubicin was especially useful in prolonging survival in the pathologic type designated acute, rather than subacute, lymphocytic leukemia. Regardless of the initial response, no patient treated a second time with daunorubicin obtained a second remission. There are seven reports in the literature describing 19 adults with acute lymphatic leukemia treated with daunorubicin alone or with prednisone. Our results indicate a less favorable response to daunorubicin than did these earlier reports. However, daunorubicin does appear to be a useful agent in adults with acute lymphatic leukemia resistant to conventional leukemia therapy.

show abstract